Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03943927 Completed - Clinical trials for Post-operative Atrial Fibrillation

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

PREEMPTIVE
Start date: March 5, 2021
Phase: N/A
Study type: Interventional

Metoprolol is frequently administered to cardiac surgery patients to reduce the incidence of postoperative atrial fibrillation (PoAF). Metoprolol is metabolized by the enzyme CYP2D6, which is known to have many mutations that could influence a patient's ability to metabolize the drug. In this prospective clinical trial, the investigators will determine the genotype of CYP2D6 for patients undergoing cardiac surgery, provide an altered dosing recommendation for metoprolol, then report the relative effectiveness in managing PoAF for each pharmacogenetic- guided dosing category. The investigators will also explore the effects of personalized metoprolol dosing recommendations on outcomes in hospital length of stay, cost, and provider participation.

NCT ID: NCT03943784 Completed - Child Clinical Trials

Endoscopic Variceal Ligation in Children

Start date: January 1, 2014
Phase:
Study type: Observational

This is an ambispective single-center cohort study of pediatric patients with portal hypertension and esophageal varices. The study was designed to evaluate the efficacy and safety of primary prophylaxis with endoscopic variceal ligation to prevent upper gastrointestinal bleeding compared to non-selected beta-blockers prophylaxis.

NCT ID: NCT03943667 Completed - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

GEMPAX
Start date: May 23, 2019
Phase: Phase 3
Study type: Interventional

This study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic Pancreatic Ductal Adenocarcinoma (PDAC) after FOLFIRINOX failure or intolerance.

NCT ID: NCT03943433 Completed - Clinical trials for Atelectasis, Postoperative Pulmonary

Oxygen Concentration During Alveolar Recruitment

Start date: May 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of oxygen concentration during alveolar recruitment on absorption ateletasis.

NCT ID: NCT03943017 Completed - Safety Issues Clinical Trials

The Inspection Campaign of French Phase I/II Research Sites Following the BIA 10-2474 Accident

HARMONY
Start date: January 1, 2017
Phase:
Study type: Observational

Following the serious adverse events that occurred in January 2016 during the BIA 10 2474 First-in-Human study, the French Ministry of Health asked the Regional Health Agencies to inspect operations at all Authorized Research Centers (ARC) conducting phase I/II clinical trials of experimental drugs.

NCT ID: NCT03942952 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.

SONICS
Start date: October 22, 2019
Phase:
Study type: Observational

Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM). The symptoms of these conditions are quite variable from patient to patient, but can include motor, sensory, visual, gait and cognitive changes. Conventional MRI can be used to look for new anatomic changes, but fails to measure underlying biochemical changes in brain tissue. The purposes of this study are to identify the biologic and anatomic correlations between cognitive profiles and disease activity using MRI imaging techniques.

NCT ID: NCT03942822 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

Chia Supplementation and Non Alcoholic Fatty Liver Disease

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease. NAFLD etiopathogeny is multifactorial, an inadequate diet characterized by high fructose content and deficient consumption of omega-3 fatty acids, scarce physical activity, excess abdominal visceral fat (AVF), insulin resistance, and genetic susceptibility have shown to be relevant determinants. Although NAFLD can progress to cirrhosis and hepatic carcinoma, its most frequent complications are type 2 diabetes mellitus (DM2) and coronary artery disease (CAD); therefore, NAFLD is considered a multisystemic disease and a public health problem. Currently, no specific pharmacological treatment is available for NAFLD, hence, modifications in life style, including weight loss by caloric restriction and increased physical activity, are still the treatment of choice for this type of patients. Recent studies indicate that the supplementation of the diet with omega-3 fatty acids of marine origin (eicosapentanoic acid [EPA]/docosahexaenoic acid [DHA]) and the Mediterranean-style diet (rich in omega-3, antioxidants, and fiber) are efficient for NAFLD treatment, because they diminish the intrahepatic fat content and improve the metabolic profile, even in non-caloric restriction diets. However, the socioeconomic and cultural characteristics make the consumption of these food difficult in some populations, which has led to the search of alternative vegetal sources rich in these nutrients. Although, there is evidence in animal models suggesting that chia (Salvia hispanica L.) could be an alternative able to reduce the intrahepatic fat content, its effect on NAFLD has not been studied in humans. Hence, the objective of this study was to analyze whether the consumption of an isocaloric diet supplemented with 25 g/day of chia can diminish NAFLD and the metabolic anomalies that accompany the disease.

NCT ID: NCT03942497 Completed - Clinical trials for Recurrent/Metastatic Urothelial Cancers

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Start date: August 1, 2019
Phase:
Study type: Observational

The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.

NCT ID: NCT03942432 Completed - Clinical trials for Dysmetabolic Iron Overload Syndrome

A Prospective, Mono-center, Interventional Study Evaluating the Effect of One Year Initial Care by Hygieno-dietary Advices With or Without Phlebotomy on Glycemia After at Least 5 Years in Patients With Dysmetabolic Iron Overload Syndrome

EvoHSD
Start date: June 11, 2019
Phase: N/A
Study type: Interventional

A prospective, mono-center, interventional study evaluating the effect of one year initial care by hygieno-dietary advices with or without Phlebotomy on glycemia after at least 5 years in Patients with dysmetabolic iron overload syndrome

NCT ID: NCT03942315 Completed - Liver Transplant Clinical Trials

Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

HHT
Start date: January 1, 2011
Phase:
Study type: Observational

Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. The investigating team provides a long-term evaluation of graft status after LT for HHT with a focus on the risk of recurrence. The present study included all patients prospectively followed up after LT for HHT in the Lyon Liver Transplant Unit from 1993 to 2010 with a survival of more than 1 year.